ClinicalTrials.gg
RecruitingNCT06238050NOBILISUpdated Jun 15, 2026

NOrmoBaric Oxygen Therapy Use In Critical Limb ISchemia

An observational study in Critical Ischemia Limb, sponsored by University Hospital, Angers. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University Hospital, Angers · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Chronic Limb-Threatening Ischemia with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · France.

Planned enrollment
7th of 11
200 · median 300
Started
2025
with 3 others
Observational
11 of 22
4 open now
Registered
15th of 22
by date
Lead sponsor
3 of 22
University Hospital, Angers

Among the 22 studies in Chronic Limb-Threatening Ischemia with a site in France, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2025, is one of 11 observational ones, and was the 15th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 22 studies in Chronic Limb-Threatening Ischemia with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Chronic Limb-Threatening Ischemia with a site in France, or all of them as a file.
02

Study summary

Peripheral arteriopathy disease (PAD) affects 1 million people in France. In its most advanced stage: chronic permanent ischemia also called critical ischemia, the prognosis of patients is burdened with a one-year mortality rate of 30%. Chronic permanent ischemia results from a lack of oxygen supply to the microcirculatory network, responsible for tissue death and the development of trophic disorders. In this context, many studies have focused on the contribution of hyperbaric oxygen therapy, however none demonstrates with certainty its beneficial effect with a heavy set-up for teams and patients. Furthermore, it appears that normobaric oxygen therapy could have its place in this context by temporarily restoring a sufficient level of transcutaneous oxygen. However, even if normobaric oxygen therapy is common practice although empirical for some practitioners, no data demonstrates its real interest. The purpose of this study is therefore to report the proportion, in usual practice, of patients with permanent chronic ischemia of the lower limb(s), benefiting from normobaric oxygen therapy, but also to show the interest of the contribution of this therapy in usual comprehensive management of these patients. This is a pilot study, after which, if the hypothesis is confirmed, it may be proposed to carry out a randomized study, on a large scale, in order to validate the use of normobaric oxygen therapy in the context of chronic permanent ischemia.

Read the detailed description

In arterial pathology of the lower limbs at the stage of chronic permanent ischemia, very few data exist on the benefit of normobaric oxygen therapy in these patients. The purpose of the present study is to report the proportion in usual practice of patients benefiting from normobaric oxygen therapy and to show the interest of the contribution of this therapy in the usual global management of patients presenting with chronic permanent ischemia of the lower limbs.

Regarding the Wound, Ischemia, Foot Infection Score (WIfI score), it includes three sub-parts, each of which has a specific evaluation grid scoring between 0 and 3. From this evaluation grid, an overall score can be calculated with different interpretations to determine the risk of amputation at one year as well as the probability of improvement in the event of revascularization, ranging from very low risk to high risk. Nevertheless, the overall evaluation of the score could mask a significant improvement in one of the items evaluated, impacting the clinical management and the future of the patient. This is why, during this study, the improvement of each item of the WIfI score separately will be studied.

The hypothesis is that putting patients in chronic permanent ischemia on oxygen therapy, which is performed frequently, brings a medical benefit compared to patients who do not benefit from it.

03

Conditions studied

  • Critical Ischemia Limb

Keywords

  • oxygen therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

hospitalized patient with symptoms of chronic permanent ischemia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient hospitalized in the recruiting centre.
  • Patient fulfilling the clinical and paraclinical criteria (resting TcpO2 values \< 30mmHg) of the definition of chronic permanent ischemia with or without trophic disorders.

Exclusion criteria

Exclusion Criteria:

  • Patient suffering from acute or decompensated heart or respiratory failure.
  • Patient suffering from (COPD) stage III or IV.
  • Patient with allergies to medical adhesives
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • hospitalized patients suspected of chronic permanent ischemia realizing transcutaneous oxymetry

    hospitalized patients suspected of chronic permanent ischemia realizing transcutaneous oxymetry are enroled in the study. The WIfI score is calculated at the inclusion.

    Procedure: introduction of oxygen therapy or not

Interventions

  • Procedureintroduction of oxygen therapy or not

    During hospitalisation, surgeon decides if patient needs and will have an oxygen therapy during this hospitalisation and at home.

06

What researchers measure

Primary outcomes

  1. Comparison of clinical characteristics of patients, whether or not they benefit from oxygen therapy in usual practices.

    Determination of patients' characteristic with or without a prescription of oxygen therapy to inventorized clinical practices.

    Time frame: 6 months

  2. Comparison of biological characteristics of patients, whether or not they benefit from oxygen therapy in usual practices.

    Determination of patients' characteristics with or without a prescription of oxygen therapy to inventorized clinical practices.

    Time frame: 6 months

Secondary outcomes

  1. Collection of all investigations carried out since inclusion and all modifications of medical therapy or implementation of surgical treatment.

    Descriptive study of investigations and therapies (medical and surgical) carried out during the patient's follow-up period

    Time frame: 6 months

  2. prevalence of decision-making parameters by using the sheet sent to the prescribing doctor by the patient.

    Descriptive study of the parameter(s) which allowed the prescriber to make the decision to implement oxygen therapy.

    Time frame: 6 months

  3. difference in the WIfI score items at inclusion and at 6 months.

    Evaluation of the evolution of chronic permanent ischemia according to the administration in current practice of normobaric oxygen therapy.

    Time frame: 6 months

  4. All-cause mortality at 6 months.

    Evaluation of the evolution of chronic permanent ischemia according to the administration in current practice of normobaric oxygen therapy.

    Time frame: 6 months

  5. occurrence of an amputation between one week after inclusion and 6 months.

    Evaluation of the evolution of chronic permanent ischemia according to the administration in current practice of normobaric oxygen therapy.

    Time frame: 6 months

  6. difference in score obtained at 1 month and at 6 months depending on the presence of chronic permanent ischemia or not and the administration of oxygen or not.

    Assessment of the quality of life of patients suspected of chronic permanent ischemia using the Vascu-QOL-6 questionnaire

    Time frame: 1 and 6 month

  7. Proportion of compliant patients in whom oxygen was prescribed on an outpatient basis

    Evaluation of compliance with oxygen for patients benefiting from it

    Time frame: 1 and 6 month

07

Study locations

1 of 3 sites recruiting
  • University Hospital
    Angers, 49933, France
    Recruiting
  • Hospital Center
    Cholet, 49325, France
    Not yet recruiting
    • Cedric MD FONTAINE · Contact
  • Hospital Center
    Le Mans, 72000, France
    Not yet recruiting
    • Claire MD NEVEUX · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 20 months is below that.

Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Feb 2, 2024
StartActual
Apr 15, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06238050
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Apr 15, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 15, 2026

Study contacts

Jeanne MD HERSANT, PhD
Contact
jeanne.hersant@chu-angers.fr
241353689 ext. +33(0)
Marine MAUBOUSSIN
Contact
marine.mauboussin@chu-angers.fr
668047430 ext. +33(0)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion